424B5 filed Jun 24, 2026 at 16:52 ET
uniQure priced a $225M underwritten public offering of 4,945,055 ordinary shares at $45.50/share, a ~7.2% discount to the prior close of $49.04. Net proceeds of ~$211M will fund commercialization readiness, a confirmatory study for lead gene therapy AMT-130 (Huntington's disease), and pipeline development. The offering comes days after the company announced FDA alignment to accept Phase I/II data as the primary basis for a BLA submission under accelerated approval, a major regulatory de-risking event. The 7.8% dilution (4.95M new shares vs 63.0M outstanding) is a near-term overhang, but the capital raise removes a key financing overhang and funds the path to a pivotal BLA filing in Q3 2026.